EP4188959A4 - Anticorps muc1* antivariables et utilisations associées - Google Patents

Anticorps muc1* antivariables et utilisations associées Download PDF

Info

Publication number: EP4188959A4
Authority: EP; European Patent Office
Prior art keywords: antivariable; muc1; antibodies; antivariable muc1
Prior art date: 2020-07-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP21850106.2A

Other languages

German (de)

English (en)

Other versions

EP4188959A1 (fr

Inventor

Cynthia Bamdad

Benoit Smagghe

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Minerva Biotechnologies Corp

Original Assignee

Minerva Biotechnologies Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-07-29

Filing date

2021-07-27

Publication date

2024-08-14

2021-07-27 Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp

2023-06-07 Publication of EP4188959A1 publication Critical patent/EP4188959A1/fr

2024-08-14 Publication of EP4188959A4 publication Critical patent/EP4188959A4/fr

Status Pending legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4256—Tumor associated carbohydrates
- A61K40/4257—Mucins, e.g. MUC-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/13—Antibody-based
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/22—Intracellular domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Hematology (AREA)
General Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)

EP21850106.2A 2020-07-29 2021-07-27 Anticorps muc1* antivariables et utilisations associées Pending EP4188959A4 (fr)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US202063058044P	2020-07-29	2020-07-29
US202063122234P	2020-12-07	2020-12-07
US202163151380P	2021-02-19	2021-02-19
US202163173083P	2021-04-09	2021-04-09
US202163184724P	2021-05-05	2021-05-05
PCT/US2021/071017 WO2022027039A1 (fr)	2020-07-29	2021-07-27	Anticorps muc1* antivariables et utilisations associées

Publications (2)

Publication Number	Publication Date
EP4188959A1 EP4188959A1 (fr)	2023-06-07
EP4188959A4 true EP4188959A4 (fr)	2024-08-14

Family

ID=80036184

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP21850106.2A Pending EP4188959A4 (fr)	2020-07-29	2021-07-27	Anticorps muc1* antivariables et utilisations associées

Country Status (8)

Country	Link
EP (1)	EP4188959A4 (fr)
JP (2)	JP7719855B2 (fr)
KR (1)	KR20230059789A (fr)
CN (1)	CN116234828A (fr)
AU (1)	AU2021316042A1 (fr)
CA (1)	CA3187555A1 (fr)
IL (1)	IL300252A (fr)
WO (1)	WO2022027039A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20230031981A (ko)	2019-05-14	2023-03-07	프로벤션 바이오, 인코포레이티드	제1형 당뇨병을 예방하기 위한 방법 및 조성물
KR20230092863A (ko)	2020-06-11	2023-06-26	프로벤션 바이오, 인코포레이티드	제1형 당뇨병을 예방하기 위한 방법 및 조성물
WO2021263227A2 (fr)	2020-06-26	2021-12-30	Minerva Biotechnologies Corporation	Anticorps anti-nme et méthode de traitement du cancer ou de métastases cancéreuses
CN119317447A (zh)	2022-04-12	2025-01-14	米纳瓦生物技术公司	抗可变muc1*抗体及其用途
US20240261406A1 (en)	2023-02-02	2024-08-08	Minerva Biotechnologies Corporation	Chimeric antigen receptor compositions and methods for treating muc1* diseases
WO2025049494A1 (fr)	2023-08-29	2025-03-06	Minerva Biotechnologies Corporation	Orthologues de nme7 bactériens et leurs utilisations
WO2025080693A1 (fr) *	2023-10-11	2025-04-17	Minerva Biotechnologies Corporation	Complexes médicament-anticorps anti-muc1 * et leurs utilisations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20180112007A1 (en) *	2015-02-10	2018-04-26	Minerva Biotechnologies Corporation	Humanized anti-muc1* antibodies
WO2019104306A1 (fr) *	2017-11-27	2019-05-31	Minerva Biotechnologies Corporation	Anticorps anti-muc1* humanisés et utilisation directe de l'enzyme de clivage
WO2019133969A2 (fr) *	2017-12-29	2019-07-04	Memorial Sloan-Kettering Cancer Center	Récepteurs antigéniques chimériques améliorés et leurs utilisations
WO2020146902A2 (fr) *	2019-01-11	2020-07-16	Minerva Biotechnologies Corporation	Anticorps muc1* antivariables et leurs utilisations

2021
- 2021-07-27 CN CN202180067049.7A patent/CN116234828A/zh active Pending
- 2021-07-27 IL IL300252A patent/IL300252A/en unknown
- 2021-07-27 CA CA3187555A patent/CA3187555A1/fr active Pending
- 2021-07-27 WO PCT/US2021/071017 patent/WO2022027039A1/fr not_active Ceased
- 2021-07-27 JP JP2023506494A patent/JP7719855B2/ja active Active
- 2021-07-27 KR KR1020237006591A patent/KR20230059789A/ko active Pending
- 2021-07-27 EP EP21850106.2A patent/EP4188959A4/fr active Pending
- 2021-07-27 AU AU2021316042A patent/AU2021316042A1/en active Pending
2024
- 2024-06-28 JP JP2024105523A patent/JP2024156662A/ja active Pending

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20180112007A1 (en) *	2015-02-10	2018-04-26	Minerva Biotechnologies Corporation	Humanized anti-muc1* antibodies
WO2019104306A1 (fr) *	2017-11-27	2019-05-31	Minerva Biotechnologies Corporation	Anticorps anti-muc1* humanisés et utilisation directe de l'enzyme de clivage
WO2019133969A2 (fr) *	2017-12-29	2019-07-04	Memorial Sloan-Kettering Cancer Center	Récepteurs antigéniques chimériques améliorés et leurs utilisations
WO2020146902A2 (fr) *	2019-01-11	2020-07-16	Minerva Biotechnologies Corporation	Anticorps muc1* antivariables et leurs utilisations

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HUGHES-PARRY HANNAH E. ET AL: "The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, no. 1, 27 December 2019 (2019-12-27), Basel, CH, pages 204, XP055977541, ISSN: 1661-6596, DOI: 10.3390/ijms21010204 *
MAJZNER ROBBIE G. ET AL: "Tuning the Antigen Density Requirement for CAR T-cell Activity", CANCER DISCOVERY, vol. 10, no. 5, 19 March 2020 (2020-03-19), US, pages 702 - 723, XP055883616, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-19-0945 *
See also references of WO2022027039A1 *
Y. ZHAO ET AL: "A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity", THE JOURNAL OF IMMUNOLOGY, vol. 183, no. 9, 1 November 2009 (2009-11-01), pages 5563 - 5574, XP055081967, ISSN: 0022-1767, DOI: 10.4049/jimmunol.0900447 *
ZHENG WENTING ET AL: "PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells", BLOOD CANCER JOURNAL, NATURE PUBLISHING GROUP UK, LONDON, vol. 32, no. 5, 2 February 2018 (2018-02-02), pages 1157 - 1167, XP036497308, ISSN: 0887-6924, [retrieved on 20180202], DOI: 10.1038/S41375-017-0008-6 *

Also Published As

Publication number	Publication date
CA3187555A1 (fr)	2022-02-03
IL300252A (en)	2023-03-01
CN116234828A (zh)	2023-06-06
JP2024156662A (ja)	2024-11-06
WO2022027039A1 (fr)	2022-02-03
JP2023537326A (ja)	2023-08-31
AU2021316042A1 (en)	2023-03-30
KR20230059789A (ko)	2023-05-03
JP7719855B2 (ja)	2025-08-06
EP4188959A1 (fr)	2023-06-07

Publication	Publication Date	Title
EP4188959A4 (fr)	2024-08-14	Anticorps muc1* antivariables et utilisations associées
EP3759143A4 (fr)	2022-03-02	Anticorps anti-tigit et leurs utilisations
EP3740224A4 (fr)	2022-05-04	Anticorps anti-lilrb et leurs utilisations
EP4141030A4 (fr)	2024-09-04	Anticorps anti-cd73 et son utilisation
IL284772A (en)	2021-08-31	Anti-variable muc1* antibodies and uses thereof
EP4359442A4 (fr)	2025-10-15	Anticorps anti-ccr8 et leurs utilisations
EP4071172A4 (fr)	2023-10-18	Anticorps anti-lilrb1 et ses utilisations
EP3735427A4 (fr)	2021-09-15	Anticorps anti-mct1 et utilisations associées
EP4039708A4 (fr)	2023-11-08	Anticorps anti-cll1 et son utilisation
EP3904382A4 (fr)	2022-07-13	Anticorps anti-il-23p19 et ses utilisations
EP4025609A4 (fr)	2023-10-04	Anticorps anti-steap1 et leurs utilisations
EP4302777A4 (fr)	2025-07-02	Anticorps anti-cldn6 et son utilisation
EP4142793A4 (fr)	2024-08-28	Anticorps spécifiques à abcb5 et leurs utilisations
EP4132569A4 (fr)	2024-07-31	Anticorps anti-phf-tau et utilisations
EP4126938A4 (fr)	2024-04-10	Anticorps se liant à siglec15 et leurs utilisations
EP4319822A4 (fr)	2024-10-16	Anticorps anti-muc1* variables et leurs utilisations
EP3790586A4 (fr)	2022-01-19	Anticorps anti-dll3 et leurs utilisations
EP3962954A4 (fr)	2023-01-18	Anticorps anti-galectine-9 et leurs utilisations
EP4247419A4 (fr)	2024-11-06	Anticorps anti-marco et utilisations associées
EP4244255A4 (fr)	2024-12-25	Anticorps anti-tigit et leurs utilisations
EP4001308A4 (fr)	2023-08-23	Anticorps anti-tigit et leur application
EP4396224A4 (fr)	2025-11-12	Anticorps anti-dll3 et leurs utilisations
EP4146272A4 (fr)	2024-10-23	Anticorps anti-covid-19 et leurs utilisations
EP4340879A4 (fr)	2025-03-26	Anticorps se liant à c1s et leurs utilisations
EP4321535A4 (fr)	2025-04-23	Anticorps anti-cntn4 et son utilisation

Legal Events

Date	Code	Title	Description
2022-02-04	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2023-05-05	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2023-05-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2023-06-07	17P	Request for examination filed	Effective date: 20230227
2023-06-07	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-08-23	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230719
2023-11-08	DAV	Request for validation of the european patent (deleted)
2023-11-08	DAX	Request for extension of the european patent (deleted)
2024-08-14	A4	Supplementary search report drawn up and despatched	Effective date: 20240715
2024-08-14	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/00 20060101ALI20240709BHEP Ipc: A61P 35/00 20060101ALI20240709BHEP Ipc: C07K 14/71 20060101ALI20240709BHEP Ipc: C07K 16/30 20060101ALI20240709BHEP Ipc: C07K 16/28 20060101AFI20240709BHEP
2025-04-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2025-05-21	17Q	First examination report despatched	Effective date: 20250417